Comparative Pharmacology
Head-to-head clinical analysis: DURAQUIN versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAQUIN versus ETHMOZINE.
DURAQUIN vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, slowing phase 0 depolarization, prolongs the action potential duration, and increases the effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Quinidine sulfate 324 mg orally every 8-12 hours, adjusted based on serum quinidine levels.
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function. Clinically, dose adjustment may be needed in renal impairment (half-life prolonged to up 18 hours) or hepatic impairment.
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Primarily hepatic metabolism (90-95%) to inactive metabolites, with renal excretion of unchanged drug <5% and metabolites. Fecal elimination accounts for <5% due to biliary excretion of metabolites.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic